Skip to main content
Top
Published in: Tumor Biology 6/2015

01-06-2015 | Research Article

Epigenetic inactivation of SOX1 promotes cell migration in lung cancer

Authors: Ning Li, Suyun Li

Published in: Tumor Biology | Issue 6/2015

Login to get access

Abstract

SOX1 is epigenetically inactivated in hepatocellular carcinoma. However, the expression and methylation status of SOX1 in non-small cell lung cancer (NSCLC) remains unknown. The aim of the current study was to investigate whether the promoter hypermethylation of SOX1 is involved in human lung carcinogenesis. We first detected the expression of SOX1 protein in a tissue microarray (TMA) of primary NSCLC and adjacent normal lung tissue specimens using immunohistochemical staining with a specific anti-SOX1 antibody. Methylation of the promoter region of SOX1 in lung cancer tissues was determined by bisulfite sequencing PCR (BSP). In the present study, we found that the SOX1 promoter was fully or partially methylated in 40 of 60 (66.7 %) tumor tissues but not in the majority 15 of 60 (25 %) of normal tissues. A statistically significant inverse association was found between SOX1 methylation status and expression of the SOX1 in tumor tissues (P = 0.003). We further demonstrate that restoration of SOX1 inhibited cell migration by regulating actin cytoskeletal remodeling. Our results suggest that SOX1 is epigenetically silenced in the majority of NSCLC and restoration of SOX1 inhibited cell migration by regulating actin cytoskeletal remodeling in NSCLC.
Literature
1.
go back to reference Kan L, Israsena N, Zhang Z, Hu M, Zhao LR, Jalali A, et al. Sox1 acts through multiple independent pathways to promote neurogenesis. Dev Biol. 2004;269(2):580–94.CrossRefPubMed Kan L, Israsena N, Zhang Z, Hu M, Zhao LR, Jalali A, et al. Sox1 acts through multiple independent pathways to promote neurogenesis. Dev Biol. 2004;269(2):580–94.CrossRefPubMed
2.
go back to reference Shih YL, Hsieh CB, Yan MD, Tsao CM, Hsieh TY, Liu CH, et al. Frequent concomitant epigenetic silencing of SOX1 and secreted frizzled-related proteins (SFRPs) in human hepatocellular carcinoma. J Gastroenterol Hepatol. 2013;28(3):551–9.CrossRefPubMed Shih YL, Hsieh CB, Yan MD, Tsao CM, Hsieh TY, Liu CH, et al. Frequent concomitant epigenetic silencing of SOX1 and secreted frizzled-related proteins (SFRPs) in human hepatocellular carcinoma. J Gastroenterol Hepatol. 2013;28(3):551–9.CrossRefPubMed
3.
go back to reference Tsao CM, Yan MD, Shih YL, Yu PN, Kuo CC, Lin WC, et al. SOX1 functions as a tumor suppressor by antagonizing the WNT/beta-catenin signaling pathway in hepatocellular carcinoma. Hepatol Baltimore Md. 2012;56(6):2277–87.CrossRef Tsao CM, Yan MD, Shih YL, Yu PN, Kuo CC, Lin WC, et al. SOX1 functions as a tumor suppressor by antagonizing the WNT/beta-catenin signaling pathway in hepatocellular carcinoma. Hepatol Baltimore Md. 2012;56(6):2277–87.CrossRef
4.
go back to reference Lai HC, Lin YW, Huang TH, Yan P, Huang RL, Wang HC, et al. Identification of novel DNA methylation markers in cervical cancer. Int J Cancer. 2008;123(1):161–7.CrossRefPubMed Lai HC, Lin YW, Huang TH, Yan P, Huang RL, Wang HC, et al. Identification of novel DNA methylation markers in cervical cancer. Int J Cancer. 2008;123(1):161–7.CrossRefPubMed
5.
go back to reference Su HY, Lai HC, Lin YW, Chou YC, Liu CY, Yu MH. An epigenetic marker panel for screening and prognostic prediction of ovarian cancer. Int J Cancer. 2009;124(2):387–93.CrossRefPubMed Su HY, Lai HC, Lin YW, Chou YC, Liu CY, Yu MH. An epigenetic marker panel for screening and prognostic prediction of ovarian cancer. Int J Cancer. 2009;124(2):387–93.CrossRefPubMed
6.
go back to reference Li N, Li X, Li S, Zhou S, Zhou Q. Cisplatin-induced downregulation of SOX1 increases drug resistance by activating autophagy in non-small cell lung cancer cell. Biochem Biophys Res Commun. 2013;439(2):187–90.CrossRefPubMed Li N, Li X, Li S, Zhou S, Zhou Q. Cisplatin-induced downregulation of SOX1 increases drug resistance by activating autophagy in non-small cell lung cancer cell. Biochem Biophys Res Commun. 2013;439(2):187–90.CrossRefPubMed
7.
go back to reference Pu J, Mao Y, Lei X, Yan Y, Lu X, Tian J, et al. FERM domain containing protein 7 interacts with the Rho GDP dissociation inhibitor and specifically activates Rac1 signaling. PLoS One. 2013;8(8):e73108.CrossRefPubMedPubMedCentral Pu J, Mao Y, Lei X, Yan Y, Lu X, Tian J, et al. FERM domain containing protein 7 interacts with the Rho GDP dissociation inhibitor and specifically activates Rac1 signaling. PLoS One. 2013;8(8):e73108.CrossRefPubMedPubMedCentral
8.
go back to reference Koga T, Takeshita M, Yano T, Maehara Y, Sueishi K. CHFR hypermethylation and EGFR mutation are mutually exclusive and exhibit contrastive clinical backgrounds and outcomes in non-small cell lung cancer. Int J Cancer. 2011;128(5):1009–17.CrossRefPubMed Koga T, Takeshita M, Yano T, Maehara Y, Sueishi K. CHFR hypermethylation and EGFR mutation are mutually exclusive and exhibit contrastive clinical backgrounds and outcomes in non-small cell lung cancer. Int J Cancer. 2011;128(5):1009–17.CrossRefPubMed
9.
go back to reference Hong KM, Yang SH, Chowdhuri SR, Player A, Hames M, Fukuoka J, et al. Inactivation of LLC1 gene in nonsmall cell lung cancer. Int J Cancer. 2007;120(11):2353–8.CrossRefPubMedPubMedCentral Hong KM, Yang SH, Chowdhuri SR, Player A, Hames M, Fukuoka J, et al. Inactivation of LLC1 gene in nonsmall cell lung cancer. Int J Cancer. 2007;120(11):2353–8.CrossRefPubMedPubMedCentral
10.
go back to reference Lin YW, Tsao CM, Yu PN, Shih YL, Lin CH, Yan MD. SOX1 suppresses cell growth and invasion in cervical cancer. Gynecol Oncol. 2013;131(1):174–81.CrossRefPubMed Lin YW, Tsao CM, Yu PN, Shih YL, Lin CH, Yan MD. SOX1 suppresses cell growth and invasion in cervical cancer. Gynecol Oncol. 2013;131(1):174–81.CrossRefPubMed
11.
go back to reference Gardberg M, Kaipio K, Lehtinen L, Mikkonen P, Heuser VD, Talvinen K, et al. FHOD1, a formin upregulated in epithelial-mesenchymal transition, participates in cancer cell migration and invasion. PLoS One. 2013;8(9):e74923.CrossRefPubMedPubMedCentral Gardberg M, Kaipio K, Lehtinen L, Mikkonen P, Heuser VD, Talvinen K, et al. FHOD1, a formin upregulated in epithelial-mesenchymal transition, participates in cancer cell migration and invasion. PLoS One. 2013;8(9):e74923.CrossRefPubMedPubMedCentral
12.
go back to reference Wilson AL, Schrecengost RS, Guerrero MS, Thomas KS, Bouton AH. Breast cancer antiestrogen resistance 3 (BCAR3) promotes cell motility by regulating actin cytoskeletal and adhesion remodeling in invasive breast cancer cells. PLoS One. 2013;8(6):e65678.CrossRefPubMedPubMedCentral Wilson AL, Schrecengost RS, Guerrero MS, Thomas KS, Bouton AH. Breast cancer antiestrogen resistance 3 (BCAR3) promotes cell motility by regulating actin cytoskeletal and adhesion remodeling in invasive breast cancer cells. PLoS One. 2013;8(6):e65678.CrossRefPubMedPubMedCentral
14.
go back to reference Valderrama F, Thevapala S, Ridley AJ. Radixin regulates cell migration and cell-cell adhesion through Rac1. J Cell Sci. 2012;125(Pt 14):3310–9.CrossRefPubMed Valderrama F, Thevapala S, Ridley AJ. Radixin regulates cell migration and cell-cell adhesion through Rac1. J Cell Sci. 2012;125(Pt 14):3310–9.CrossRefPubMed
15.
go back to reference Schlunck G, Damke H, Kiosses WB, Rusk N, Symons MH, Waterman-Storer CM, et al. Modulation of Rac localization and function by dynamin. Mol Biol Cell. 2004;15(1):256–67.CrossRefPubMedPubMedCentral Schlunck G, Damke H, Kiosses WB, Rusk N, Symons MH, Waterman-Storer CM, et al. Modulation of Rac localization and function by dynamin. Mol Biol Cell. 2004;15(1):256–67.CrossRefPubMedPubMedCentral
Metadata
Title
Epigenetic inactivation of SOX1 promotes cell migration in lung cancer
Authors
Ning Li
Suyun Li
Publication date
01-06-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3107-x

Other articles of this Issue 6/2015

Tumor Biology 6/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine